Literature DB >> 31724237

HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with huntington's disease.

Noelle E Carlozzi1, Nicholas R Boileau1, Kelvin L Chou2, Rebecca E Ready3, David Cella4, Michael K McCormack5,6, Jennifer A Miner1, Praveen Dayalu2.   

Abstract

BACKGROUND: Huntington's disease (HD) is a neurological disorder that causes severe motor symptoms that adversely impact health-related quality of life. Patient-reported physical function outcome measures in HD have shown cross-sectional evidence of validity, but responsiveness has not yet been assessed.
OBJECTIVES: This study evaluates the responsiveness of the Huntington Disease Health-Related Quality of Life (HDQLIFE) and the Quality of Life in Neurological Disorders (Neuro-QoL) physical function measures in persons with HD.
METHODS: A total of 347 participants completed baseline and at least 1 follow-up (12-month and 24-month) measure (HDQLIFE Chorea, HDQLIFE Swallowing Difficulties, HDQLIFE Speech Difficulties, Neuro-QoL Upper Extremity Function, and/or Neuro-QoL Lower Extremity Function). Of the participants that completed the baseline assessment, 338 (90.9%) completed the 12-month assessment, and 293 (78.8%) completed the 24-month assessment. Standardized response means and general linear models evaluated whether the physical function measures were responsive to self-reported and clinician-rated change over time.
RESULTS: Small to moderate effect sizes for the standardized response means supported 12-month and 24-month responsiveness of the HDQLIFE and Neuro-QoL measures for those with either self-reported or clinician-rated declines in function. General linear models supported 12-month and 24-month responsiveness for all HRQOL measures relative to self-reported declines in health, but generally only 24-month responsiveness was supported relative to clinician-rated declines in function.
CONCLUSIONS: Longitudinal analyses indicate that the HDQLIFE and the Neuro-QoL physical function measures are sensitive to change over time in individuals with HD. Thus, these scales exhibit evidence of responsiveness and may be useful outcome measures in future clinical trials.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; health-related quality of life; patient-reported outcome (PRO); psychometric; validity

Mesh:

Year:  2019        PMID: 31724237      PMCID: PMC7041888          DOI: 10.1002/mds.27908

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  55 in total

1.  Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life.

Authors:  K W Wyrwich; W M Tierney; F D Wolinsky
Journal:  J Clin Epidemiol       Date:  1999-09       Impact factor: 6.437

Review 2.  Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference.

Authors:  D E Beaton; C Bombardier; J N Katz; J G Wright; G Wells; M Boers; V Strand; B Shea
Journal:  J Rheumatol       Date:  2001-02       Impact factor: 4.666

3.  Responsiveness of generic health-related quality of life measures in stroke.

Authors:  A Simon Pickard; Jeffrey A Johnson; David H Feeny
Journal:  Qual Life Res       Date:  2005-02       Impact factor: 4.147

4.  Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures.

Authors:  Noelle E Carlozzi; Rebecca E Ready; Samuel Frank; David Cella; Elizabeth A Hahn; Siera M Goodnight; Stephen G Schilling; Nicholas R Boileau; Praveen Dayalu
Journal:  Mov Disord       Date:  2017-05-27       Impact factor: 10.338

5.  Sample enrichment for clinical trials to show delay of onset in huntington disease.

Authors:  Jane S Paulsen; Spencer Lourens; Karl Kieburtz; Ying Zhang
Journal:  Mov Disord       Date:  2019-01-14       Impact factor: 10.338

6.  Development and validation of the positive affect and well-being scale for the neurology quality of life (Neuro-QOL) measurement system.

Authors:  John M Salsman; David Victorson; Seung W Choi; Amy H Peterman; Allen W Heinemann; Cindy Nowinski; David Cella
Journal:  Qual Life Res       Date:  2013-03-23       Impact factor: 4.147

7.  Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study.

Authors:  Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Julie C Stout
Journal:  Biol Psychiatry       Date:  2007-05-03       Impact factor: 13.382

8.  Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients.

Authors:  K C Sneeuw; N K Aaronson; M A Sprangers; S B Detmar; L D Wever; J H Schornagel
Journal:  J Clin Epidemiol       Date:  1998-07       Impact factor: 6.437

9.  Exercise testing and training in people with Huntington's disease.

Authors:  H Dawes; J Collett; K Debono; L Quinn; K Jones; M J Kelson; S A Simpson; R Playle; K Backx; D Wasley; A H Nemeth; A Rosser; H Izardi; M Busse
Journal:  Clin Rehabil       Date:  2014-08-20       Impact factor: 3.477

10.  Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study.

Authors:  Jane S Paulsen; Jeffrey D Long; Hans J Johnson; Elizabeth H Aylward; Christopher A Ross; Janet K Williams; Martha A Nance; Cheryl J Erwin; Holly J Westervelt; Deborah L Harrington; H Jeremy Bockholt; Ying Zhang; Elizabeth A McCusker; Edmond M Chiu; Peter K Panegyres
Journal:  Front Aging Neurosci       Date:  2014-04-22       Impact factor: 5.750

View more
  4 in total

1.  Responsiveness and interpretation of the PROMIS Cancer Function Brief 3D Profile.

Authors:  Sean R Smith; Mary Vargo; David S Zucker; Samman Shahpar; Lynn H Gerber; Maryanne Henderson; Gina Jay; Andrea L Cheville
Journal:  Cancer       Date:  2022-07-05       Impact factor: 6.921

2.  Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD).

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Matthew W Roché; Rebecca E Ready; Joel S Perlmutter; Kelvin L Chou; Stacey K Barton; Michael K McCormack; Julie C Stout; David Cella; Jennifer A Miner; Jane S Paulsen
Journal:  Qual Life Res       Date:  2020-08-19       Impact factor: 4.147

3.  Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.

Authors:  Noelle E Carlozzi; Nicholas R Boileau; Angela Roberts; Praveen Dayalu; Dana L Hanifan; Jennifer A Miner; Daniel Claassen; Emily Mower Provost
Journal:  Qual Life Res       Date:  2020-08-24       Impact factor: 4.147

4.  Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life.

Authors:  Leonard L Sokol; Jonathan P Troost; Benzi M Kluger; Allison J Applebaum; Jane S Paulsen; Danny Bega; Samuel Frank; Joshua M Hauser; Nicholas R Boileau; Colin A Depp; David Cella; Noelle E Carlozzi
Journal:  Ann Clin Transl Neurol       Date:  2021-07-20       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.